Cholesterol Lowering Biologic Drugs Market

The cholesterol lowering biologic drugs offers a new, revolutionary alternative for people fighting with cholesterol with the same old treatments. The old method of treating cholesterol elevated levels includes a change in diet and consuming statin pills to prevent the body from making more bad cholesterol. The new class of PCSK-9 inhibitors is being approved by the FDA which works by helping the liver flush out the bad cholesterol instead of preventing the body from making low-density lipoproteins. The FDA has till now approved only two drugs Praluent and Repatha, both made from living things. The PCSK-9 is a protein which binds to the receptors, those which are responsible for getting the bad cholesterol out of the body.
Cholesterol Lowering Biologic Drugs Market contains market size and forecasts of Cholesterol Lowering Biologic Drugs in global, including the following market information:
Global Cholesterol Lowering Biologic Drugs Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Cholesterol Lowering Biologic Drugs Market Sales, 2017-2022, 2023-2028, (K MT)
Global top five Cholesterol Lowering Biologic Drugs companies in 2021 (%)
The global Cholesterol Lowering Biologic Drugs market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Oral Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Cholesterol Lowering Biologic Drugs include Amgen, Regeneron Pharmaceuticals and Alnylam Pharmaceuticals, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Cholesterol Lowering Biologic Drugs manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Cholesterol Lowering Biologic Drugs Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K MT)
Global Cholesterol Lowering Biologic Drugs Market Segment Percentages, by Type, 2021 (%)
Oral
Injectable
Global Cholesterol Lowering Biologic Drugs Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K MT)
Global Cholesterol Lowering Biologic Drugs Market Segment Percentages, by Application, 2021 (%)
Hospital Pharmacies
Retail Pharmacies
Drug Stores
Online Sales
Global Cholesterol Lowering Biologic Drugs Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K MT)
Global Cholesterol Lowering Biologic Drugs Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Cholesterol Lowering Biologic Drugs revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Cholesterol Lowering Biologic Drugs revenues share in global market, 2021 (%)
Key companies Cholesterol Lowering Biologic Drugs sales in global market, 2017-2022 (Estimated), (K MT)
Key companies Cholesterol Lowering Biologic Drugs sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Amgen
Regeneron Pharmaceuticals
Alnylam Pharmaceuticals